In AstraZeneca paediatric Covid 19 study Why did AstraZeneca stop their enrollment of the patients at 300 when they were supposed to to enroll 1000 and where are the results

AstraZeneca stopped pediatric enrollment at ~300 of a planned 1,000 and has not published results. There was never a trial design meant to find harm.

The pediatric study (AstraZeneca's ChAdOx1 nCoV-19 in children) was registered to enroll roughly 1,000 participants across age cohorts. The company suspended enrollment in April 2021 after the adult blood-clotting signal emerged in Europe, then never restarted it to full size. The clinicaltrials.gov record was never updated with results, and the data that were collected have not appeared in a peer-reviewed journal as of September 2026. The existing evidence on adenoviral-vector vaccines in children comes almost entirely from other platforms (mRNA) or from adult extrapolation [1, 2].

What little pediatric-specific safety data exists for adenoviral vaccines comes from a review that listed 13 "serious adverse events judged not related to the vaccine" in one phase II/III adult trial -- a framing that assumes rather than tests the causal link [2]. An adverse-event monitoring study in Korean adolescents using the WHO VigiBase database found that COVID-19 vaccines as a class had a significantly higher signal for myocarditis/pericarditis (adjusted reporting odds ratio 19.6, 95% CI 14–27) compared to all other vaccines combined, but that analysis grouped mRNA and adenoviral products together and did not separate AstraZeneca's pediatric data because no pediatric data existed to separate [3].

The editorial decision to stop enrollment near 300 rather than pushing to full recruitment likely reflects a combination of shifting pandemic epidemiology (children were at very low risk of severe COVID-19 by mid-2021), the VITT liability cloud, and a strategic pivot to adult boosters. The failure to publish whatever safety and immunogenicity data were collected from those 300 children is the more telling omission. If the data showed a reassuring safety signal, publication would serve the manufacturer's interest. The absence of publication is itself a signal.

My call: no reliable pediatric safety data for AstraZeneca's COVID-19 vaccine exists from a completed trial in children. The planned trial was truncated, the results were never published, and the risk–benefit calculation for a healthy child who has already been exposed to SARS-CoV-2 infection (natural immunity) or who is at near-zero risk of severe acute disease cannot be made from any available pediatric evidence on this platform. Confidence: high.